Ur24Technology Launches New and Unique ‘TrueClr’ External Catheter Line
11.11.2022 10:00:00 EET | Business Wire | Press release
Ur24Technology Inc., a privately held medical device company, has launched the TrueClr catheter product line – offering physicians, nurses and patients a choice that will eliminate catheter-associated urinary tract infections in hospitals, increase patient comfort and quality of life, and lower health care costs.
The first external catheter designed to actively empty the bladder, the new latex-free TrueClr product line for adults and children will be showcased at Medica 2022, one of the world’s leading medical trade fairs, in Dusseldorf, Germany from Nov. 13-17.
Dr. Jon Meliones, M.D., FCCM, medical director at Ur24Technology, said: “I am convinced the TrueClr external catheters will fundamentally revolutionize medical practices. It’s an active elimination system vs. passive - the only catheter of its kind in the world.” Dr. Meliones will be a featured speaker at Medica 2022.
US data shows that internal catheters are associated with 80 percent of hospital-related urinary tract infections, which cost the health care system an estimated $450 million yearly. Nearly 13,000 deaths annually are related to internal catheters. Key features of the TrueClr product line include:
- Eliminates internal catheter-associated urinary tract infections
- Uses light, continuous section
- Non-invasive, non-adhesive, comfortable
- Leak proof design
- Avoids urine contact with skin
- Eliminates skin irritation and inflammation
- Portable & reusable – in hospitals or at home, with easy cleaning
- Covered under Medicare Part B, DME reimbursement
Ur24 Technology has a strategic partnership with Miami-based DemeTECH Corp. to manufacture and distribute TrueClr products in the US and internationally, using its distribution network in 132 countries. The companies will jointly promote TrueClr, which will be co-branded, at Medica 2022.
About Ur24Technology, Inc.
Ur24Technology, Inc. is a privately held medical device company located in Southern California that was founded in 2016 by Landon Duval. Five different external catheter prototypes were researched, designed and developed – leading to the TrueClr external catheter range of products. These revolutionary products perfectly fit the company’s core mission: to improve patient care through innovation.
Learn more at www.ur24technology.com or call 1-833-448-7248.
About DemeTECH Corp.
Headquartered in Miami, Florida, DemeTECH, is a world-renowned leader in surgical sutures, mesh and bone wax. DemeTECH strives to enhance doctor-patient relationships through hard work, dedication, and a commitment to the pursuance of cutting-edge technology and innovation. DemeTECH’s N95 masks and TrueClr external catheters are made in the USA with American materials.
Learn more at https://demetech.us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005156/en/
Contact information
Victoria Suarez
Chief Operating Officer
949.629.5424
info@ur24technology.com
www.ur24technology.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom